Technology ID
TAB-4834
Soluble Antigen-Based ELISA for the Detection of B. malayi Infections
E-Numbers
E-009-2014-0
Lead Inventor
Nutman, Thomas (NIAID)
Applications
Therapeutics
Diagnostics
Development Stages
Analytical Assay Performance Stage
Lead IC
NIAID
ICs
NIAID
The technology presented is a breakthrough in the diagnosis of lymphatic filariasis, specifically targeting the B. malayi pathogen. It encompasses a novel soluble antigen extract used in both IgG and IgG4-based ELISA tests, aimed at detecting the presence of the filarial infection. This innovation serves as a cornerstone for a CLIA-certified reference test, established and utilized in Dr. Nutman's laboratory since the late 1980s. It offers a significant advancement in the field, particularly beneficial for remote areas where traditional PCR methods are challenging to implement, thereby facilitating more accessible point-of-care diagnostics for B. malayi infection.
Commercial Applications
The ELISA technology for B. malayi has vast potential applications including widespread field diagnostics in endemic regions, integration into routine health screenings, and use in epidemiological surveillance programs. It also holds promise for facilitating ongoing research in filarial diseases and could be adapted for mass drug administration monitoring, enhancing global efforts to control and eventually eliminate lymphatic filariasis.
Competitive Advantages
The ELISA test for B. malayi provides a fast, cost-effective, and highly accurate diagnosis of lymphatic filariasis, outperforming traditional methods with its ease of use in field conditions and proven reliability, streamlining disease management in resource-limited settings.
Licensing Contact: